Please assess the completion status of the following clinical trial:

Trial Title: Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Active choroidal neovascularization (CNV) due to AMD.~2. Prior treatment with at least 4 injections of anti-VEGF agents in the past 6 months and persistent intraretinal and/or subretinal fluid on SD-OCT at each visit during this period.~3. Baseline CST ≥ 270 µm on SD-OCT automated retinal thickness map.~4. Injection of the same anti-VEGF agent at each of the two visits immediately preceding study enrollment.~5. Time interval of 5 weeks (± 1 week) between visits for at least two visits immediately preceding study enrollment.~6. Subjects of either gender aged ≥ 45 years.~7. Provide written informed consent~8. Ability to comply with study and follow-up procedures and return for study visits.~Exclusion Criteria:~1. History of uveitis.~2. Presence of intraocular inflammation, significant epiretinal membrane (causing distortion of macular anatomy per investigator discretion), significant vitreomacular traction (per investigator discretion), macular hole, or vitreous hemorrhage.~3. Any ophthalmic surgery within previous 6 months, including cataract extraction.~4. Any history of vitrectomy or glaucoma surgery (e.g., trabeculectomy, tube shunt).~5. Current prescription eye drop usage (e.g., glaucoma drops, corticosteroid drops, etc.).~6. Any contraindication for topical use of a beta-blocker (e.g., bradycardia, decompensated heart failure, chronic obstructive pulmonary disease, reactive airway disease, asthma, etc.).~7. Any history of sulfonamide allergy.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dorzolamide-timolol (Type: ACTIVE_COMPARATOR): Topical dorzolamide-timolol twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.
- Artificial tears (Type: PLACEBO_COMPARATOR): Topical artificial tears twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.

Based on this trial design, predict the completion outcome and termination type (if applicable).